Influence of Aliskiren on Albuminuria After Kidney Transplantation
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The study is a randomised, double-blind, controlled 2 x 3 cross-over trial in which the renal
effects of therapy with aliskiren (A), placebo (P) and losartan (L) will be compared. It
consists of an 8-week run-in period, 8 weeks of active treatment with aliskiren or losartan
(period 1), 8 weeks of active treatment with the alternative medication (period 2), and an
8-week placebo administration between them.